Clindamycin-Vertex, 2% vaginal cream 20 g

Bacteriostatic antibiotic from the group of lincosamides, has a broad spectrum of action, binds to 50S subunit of ribosomal membrane and inhibits protein synthesis in the microbial cell.

Bactericidal action is possible against a number of Gram-positive cocci.

Active against Staphylococcus spp. (including Staphylococcus epidermidis producing and non-producing penicillinase), Streptococcus spp. (excluding Enterococcus faecalis), Streptococcus pneumoniae, Corynebacterium diphtheriae, Mycoplasma spp, anaerobic and microaerophilic gram-positive cocci (including Peptococcus spp. and Peptostreptococcus spp.), Clostridium perfringens, Clostridium tetani, Bacteroides spp. (including Bacteroides fragilis and Prevotella melaninogenica), Fusobacterium spp., Propionibacterium spp., Eubacterium spp., and Actinomyces israelii.

Most strains of Clostridium perfringens are sensitive to clindamycin, but other species of Clostridium spp. (including Clostridium sporogenes, Clostridium tertium) are resistant to its action; therefore, in infections caused by Clostridium spp.
There is cross-resistance between clindamycin and lincomycin.

Indications

Vaginitis caused by microorganisms sensitive to drugs.

Pharmacological effect

A bacteriostatic antibiotic from the lincosamide group, has a broad spectrum of action, binds to the 50S subunit of the ribosomal membrane and inhibits protein synthesis in the microbial cell.

A bactericidal effect is possible against a number of gram-positive cocci.

Active against Staphylococcus spp. (including Staphylococcus epidermidis, producing and non-producing penicillinase), Streptococcus spp. (excluding Enterococcus faecalis), Streptococcus pneumoniae, Corynebacterium diphtheriae, Mycoplasma spp., anaerobic and microaerophilic gram-positive cocci (including Peptococcus spp. and Peptostreptococcus spp.), Clostridium perfringens, Clostridium tetani, Bacteroides spp. (including Bacteroides fragilis and Prevotella melaninogenica), Fusobacterium spp., Propionibacterium spp., Eubacterium spp., and Actinomyces israelii.

Most strains of Clostridium perfringens are sensitive to clindamycin, but other Clostridium spp. (including Clostridium sporogenes, Clostridium tertium) are resistant to its action, and therefore for infections caused by Clostridium spp., it is recommended to determine an antibiogram.
Cross-resistance exists between clindamycin and lincomycin.

Special instructions

Vaginal cream is not recommended for use simultaneously with other intravaginal drugs.

Active ingredient

Clindamycin

Pregnancy

During pregnancy, it is possible if the expected effect of therapy outweighs the potential risk to the fetus (adequate and strictly controlled studies have not been conducted in pregnant women; clindamycin passes through the placenta and can concentrate in the fetal liver, but no complications have been reported in humans).

Studies have not determined whether treating bacterial vaginosis reduces the risk of adverse pregnancy outcomes such as premature rupture of membranes, preterm labor, or preterm delivery.

Caution should be exercised when used during breastfeeding (it is unknown whether clindamycin passes into breast milk after topical and intravaginal use, but is found in breast milk after oral or parenteral administration).

Contraindications

Hypersensitivity, pregnancy first trimester (for vaginal cream).

Side Effects

Allergic reactions (including skin rash, urticaria).

Irritation at the site of application, cervicitis, vaginitis, development of superinfection (fungal vaginitis).

Interaction

Incompatible with solutions containing B complex vitamins, aminoglycosides, ampicillin, phenytoin, barbiturates, aminophylline, calcium gluconate and magnesium sulfate.

In vitro, antagonism of clindamycin with erythromycin, as well as with chloramphenicol, has been shown; Because this effect may be clinically significant, these drugs should not be taken simultaneously.

Since clindamycin interferes with neuromuscular transmission and may enhance the effects of peripherally acting muscle relaxants, caution should be used and the patient should be closely monitored during concurrent use.

When used simultaneously with opioid (narcotic) analgesics, respiratory depression may increase, including apnea. Simultaneous administration with antidiarrheal drugs that reduce gastrointestinal motility increases the risk of developing pseudomembranous colitis.

Overdose

Symptoms: increased severity of side effects.

Treatment: symptomatic and supportive. It is not excreted by hemodialysis and peritoneal dialysis.

Storage conditions

In a dry place, protected from light, at a temperature not exceeding 20 °C

Shelf life

2 years

Manufacturer

Vertex, Russia